Akebia Therapeutics (NASDAQ:AKBA) Downgraded by StockNews.com to Sell
Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Monday. Separately, HC Wainwright reissued a “buy” rating and issued a $7.50 target price on shares of Akebia Therapeutics in a research report on Wednesday, October […]
More Stories
Acumen Pharmaceuticals (NASDAQ:ABOS) Releases Quarterly Earnings Results, Misses Estimates By $0.14 EPS
Acumen Pharmaceuticals (NASDAQ:ABOS – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.50) earnings per...
LCI Industries (NYSE:LCII) to Issue Dividend Increase – $1.15 Per Share
LCI Industries (NYSE:LCII – Get Free Report) declared a quarterly dividend on Thursday, November 14th,RTT News reports. Shareholders of record...
CleanSpark (NASDAQ:CLSK) vs. Binah Capital Group (NASDAQ:BCG) Head-To-Head Comparison
CleanSpark (NASDAQ:CLSK – Get Free Report) and Binah Capital Group (NASDAQ:BCG – Get Free Report) are both finance companies, but...
ADVFN (LON:AFN) Shares Down 8.1% – What’s Next?
ADVFN Plc (LON:AFN – Get Free Report)’s share price dropped 8.1% during mid-day trading on Thursday . The company traded...
ICC Labs (CVE:ICC) Trading Down 5.8% – What’s Next?
ICC Labs Inc. (CVE:ICC – Get Free Report) dropped 5.8% during mid-day trading on Thursday . The stock traded as...
Vanguard Core Bond ETF (NASDAQ:VCRB) Short Interest Update
Vanguard Core Bond ETF (NASDAQ:VCRB – Get Free Report) was the target of a large growth in short interest in...